Navigation Links
Immunodeficient patients with secondary lung disease benefit from combined chemotherapy
Date:8/30/2012

A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).The findings are published in the Journal of Clinical Immunology.

Common variable immunodeficiency (CVID) is the most common primary immunodeficiency that requires regular treatment with medication, specifically immunoglobulin (antibodies) replacement therapy. With immunoglobulin therapy, deaths from infection in patients with CVID have decreased and deaths due to non-infectious complications have increased. One of the most frequent causes of death now in CVID is a lung disease known as granulomatous-lymphocytic interstitial lung disease (GLILD). In GLILD, white blood cells abnormally accumulate in the lung, which leads to a progressive decline in lung function and, eventually, respiratory failure. The researchers evaluated patients with GLILD to see if rituximab and azathioprine (combination chemotherapy) would improve pulmonary function and/or radiographic abnormalities by killing these white blood cells in the lung.

"The most common medication used for GLILD are corticosteroids but in our hands this type of medication did not clear the disease. Therefore, we designed therapy aimed at killing the specific type of lymphocytes, B cells and T cells, we found in abnormal numbers in the lung biopsies we examined. We reasoned if we killed the lymphocytes in the lung, lung function and radiographic abnormalities would both improve, which is what we found." said John M. Routes, M.D., professor and chief of asthma, allergy and immunology at the Medical College of Wisconsin (MCW), medical director of allergy/clinical immunology at Children's Hospital and researcher at the Research Institute.


'/>"/>

Contact: Maureen Mack
mmack@mcw.edu
414-955-4700
Medical College of Wisconsin
Source:Eurekalert

Page: 1

Related medicine news :

1. Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed
2. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
3. Confusion Over Diabetes Types Adds to Patients Woes
4. TAVI restricted to very old or very sick patients
5. Mayo study: Exercise can help cancer patients, but few oncologists suggest it
6. Exploring exercise benefits for breast cancer patients
7. Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
8. Early Stenting Best for Some Heart Patients: Study
9. Global platelet reactivity identifies high risk ACS patients
10. Global platelet reactivity and high risk ACS patients
11. TAVI improves quality of life in patients with severe aortic stenosis for at least 1 year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... ... cold therapy products, announced today the introduction of the newly designed, innovative shoulder ... comfort and better cold therapy coverage for the injured arm and shoulder to ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... grout cleaning and sealing company , is proud to announce that many of ... superior levels of customer service. The hard surface restoration franchises received customer recognition ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... Prize has officially been won. A team from 21st Century Medicine (21CM) ( ... way to preserve the delicate neural circuits of an intact rabbit brain for ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag ... into the Food & Beverage and Dietary Supplement market ... throughout Canada and USA geographies east of the Rocky Mountains since 2012. ...
(Date:2/8/2016)... Texas (PRWEB) , ... February 08, 2016 , ... The Valentine’s Season is famous for ... members and significant others that they are loved. This year, for more than 5.6 ... they cost - just won't be enough to remind them of the lives they’ve led ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 8, 2016  Echo Therapeutics, Inc. (Nasdaq: ... focused on non-invasive continuous glucose monitoring (CGM) ... that it will host a webcast and ... at 9:00 a.m. Eastern Time to provide ... strategy, advancements in its CGM system, and ...
(Date:2/8/2016)... In a historic vote among its members this weekend, the Shinnecock Indian ... facility and dispensary on tribal land near Southampton . ... provider for patients in the state,s Medical Cannabis Program. --> ... patients in the state,s Medical Cannabis Program. --> Tribal ... pursue designation from the State of New York ...
(Date:2/8/2016)... , Switzerland and PALO ALTO, Calif. , ... biological and chemical manufacturing, and Kodiak Sciences Inc., a ... treatment of retinal disease, announced today agreements for the ... Lonza will manufacture material at multiple sites, including Slough ... --> --> Retinal diseases, such ...
Breaking Medicine Technology: